Nanosponge drug delivery system for recurrent vaginal yeast infections

Overview

Nanosponge (NS) technology presents a revolutionary approach to treating recurrent vaginal yeast infections, a significant health issue for women. Traditional antifungal treatments often lead to resistance and recurrence, complicating the condition. The nanosponge drug delivery system is designed to provide a targeted, sustained release of antifungal medication directly to the infected area, reducing the risk of resistance and recurrence while minimizing side effects. This approach aims to enhance treatment efficacy and provide long-term stability.

Technical specifications

Key features:

• Sustained drug release: Provides a constant rate of drug delivery over an extended period, ensuring effective treatment.
• High payload and solubilization capacity: Capable of carrying significant amounts of medication and dissolving in both water and organic solvents.
• Temperature stability: Can withstand temperatures up to 300℃, ensuring durability under various conditions.
• Easy scalability: Designed for straightforward scaling up of production, facilitating broader application.
• In vitro and ex vivo testing: Includes drug diffusion studies, release kinetics, and stability evaluations to ensure effectiveness and reliability.

Technology readiness level

Currently at Technology Readiness Level 3, the nanosponge delivery system is undergoing validation. Physicochemical evaluations and formulation optimization are underway, with future steps involving extensive testing of antifungal effectiveness, minimum inhibitory concentration, and formulation properties such as texture and porosity. This stage involves both in vitro and ex vivo studies to confirm the system's potential for commercial deployment.